SecBot SecBot
PRESS-RELEASE ·Filed Apr 13, 2026

SYRE

Spyre Therapeutics, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The strong Phase 2 data supports SPY001 as a best-in-class anti-α4β7 candidate, with potential for accelerated development. Traders should monitor upcoming data readouts for SPY002 (mid-2026) and SPY003 (Q3 2026), as well as enrollment trends in combination arms, which could further de-risk the pipeline and attract partnership interest.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$63.27
T+0 close · Apr 13, 2026 · via day close
Latest settled
+50.78%
T+60 · $95.40
Vs SPY
+41.86%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 13 $63.27entry
  2. T+1 · 7mo ago +1.17%α −0.04% · $64.01
  3. T+5 · 7mo ago +15.99%α +12.70% · $73.39
  4. T+20 · 6mo ago +20.80%α +13.07% · $76.43
  5. T+60 · 4mo ago +50.78%α +41.86% · $95.40
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Spyre Therapeutics announced positive 12-week induction data from Part A of its Phase 2 SKYLINE trial, showing SPY001 achieved a statistically significant 9.2-point reduction in RHI score (p<0.0001) with strong secondary outcomes and a favorable safety profile. Enrollment has closed for Part A and moved to Part B, which includes monotherapy and combination cohorts, with data readouts expected through 2026–2027.

Key Facts

  • SPY001 met primary endpoint with 9.2-point reduction in RHI score (p<0.0001) at Week 12 in Phase 2 SKYLINE trial Part A.
  • Secondary endpoints: 40% clinical remission rate and 51% endoscopic improvement rate.
  • SPY001 was well tolerated with no drug-related serious adverse events; most common AE was back pain (n=2).
  • Part B of the SKYLINE trial is now enrolling, including combination cohorts with SPY002 and SPY003.
  • Proof-of-concept data for SPY002 expected mid-2026, SPY003 in Q3 2026, and full Part B data in 2027.

Financial Impact

Potential blockbuster profile for SPY001 in ulcerative colitis, with best-in-class positioning and combination potential driving valuation upside.

marketCappipelineValuerevenueExpectations

Risk Factors

  • Future data may not confirm current results, especially in randomized, placebo-controlled Part B.
  • Regulatory disagreement with trial design or endpoints could delay approval path.
  • Competition from existing anti-integrin and anti-cytokine therapies in IBD space.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3272353

Track record

36 reports on SYRE

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+60. Best: +54.27% at T+60 after the Apr 13, 2026 report. 14 of 20 went positive at some point.

Filters
  1. Nov 3, 202613d ago 8-K Neutral 5/10 No price data
  2. Nov 3, 202613d ago Press Release Bearish 5/10 Entry $99.04 Now $99.37 −0.33% settles Feb 2
  3. Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
  4. Oct 9, 20265w ago SC 13D/A Neutral 3/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
  5. Oct 7, 20265w ago 8-K Bearish 5/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
  6. Oct 6, 20265w ago 424B5 Bearish 6/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
  7. Oct 5, 20266w ago Press Release Bearish 6/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  8. Oct 5, 20266w ago 424B5 Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  9. Oct 5, 20266w ago Press Release Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  10. Oct 2, 20266w ago Insider Cluster Bearish 4/10 Entry $92.72 Now $99.37 −7.17% settles Dec 30
Showing 10 of 36

US Market Status

Market Closed · Opens Wed (9h 31m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 13, 2026